MedTrace Logo

Albumin-bound Paclitaxel-based Second-line Treatment Regimens for Locally Advanced or Metastatic G/GEJ Adenocarcinoma

NCT07389876 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 250

Last updated 2026-02-05

No results posted yet for this study

Summary

This study is an open-label, multi-cohort real-world research that explores the efficacy and safety of different second-line treatment regimens for gastric/gastroesophageal junction adenocarcinoma that has failed first-line fluoropyrimidine, platinum-based chemotherapy combined with immunotherapy.

Conditions

Interventions

DRUG

Albumin-bound Paclitaxel

This is a prospective observational study. We observe efficacy and survival of different treatment regimen.

DRUG

Immune Checkpoint Inhibitor

Immune Checkpoint Inhibitor

DRUG

Anti-angiogenic drug

Anti-angiogenic drug

DRUG

Trastuzumab emtansine

Trastuzumab Emtansine

Sponsors & Collaborators

  • Fudan University

    lead OTHER

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-09-01
Primary Completion
2027-09-01
Completion
2028-09-01

Countries

  • China

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07389876 on ClinicalTrials.gov